Survivin Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Survivin inhibitor is a class of pharmaceutical compounds designed to target and inhibit the survivin protein, which plays a crucial role in regulating apoptosis (programmed cell death) and promoting cell survival. By blocking survivin, these inhibitors aim to induce apoptosis in cancer cells, hindering tumor growth and potentially improving cancer treatment outcomes. Survivin inhibitors have been primarily investigated for their potential in various cancer types, including breast, lung, colon, ovarian, and prostate cancers, where survivin is frequently overexpressed. According to the World Health Organization (WHO), cancer remains a significant health challenge in Europe and the USA, with millions of new cases reported annually. Breast cancer is one of the most common malignancies, affecting approximately 2.1 million women each year worldwide, as per WHO statistics. Lung cancer also poses a substantial burden, with over 2.2 million new cases worldwide, and colorectal cancer accounts for nearly 1.8 million cases annually. Ovarian cancer affects around 313,000 women globally, while prostate cancer remains a significant concern for men, with over 1.4 million new cases reported annually.

Growth drivers for the Survivin inhibitor market include promising clinical trial results, demonstrating their efficacy in specific cancer types, along with the increasing adoption of personalized medicine and targeted therapies. Companies such as Marker Therap, AbbVie, Astellas, Cothera Biosci, EMD Serono, Eli Lilly, Enzon, and Erimos are pharmaceutical companies operating in the healthcare industry. cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Cothera Bioscience is currently conducting a clinical trial of the drug PC-002 for the treatment of lymphoma.

Key Developments

  • In Feb 2023, IMV released safety and efficacy data from a phase IIb VITALIZE trial of Maveropepimut in diffuse large B cell lymphoma.
  • In Dec 2022, MimiVax released final efficacy and adverse event data from a phase II trial of SVN 5367 in Glioblastoma.

Approved Survivin Inhibitor Molecules

  • CINelim (terameprocol)
  • MultiTAA T cell therapy

Survivin Inhibitor Pipeline Molecules

  • maveropepimut-S (MVP-S)
  • sepantronium bromide (PC-002)
  • gataparsen (LY2181308)
  • IO101
  • MT-601
  • SL-701
  • ABBV-184
  • MANA-312
  • NEXI-003       

Clinical Activity and Development of Survivin Inhibitor

In the Survivin Inhibitor space, there are very few companies, conducting more than more than 50 clinical trials in this category of drugs. For instance,

  • In April 2023, IMV presented efficacy data from a phase I/II DeCidE1 trial of Maveropepimut S in Ovarian cancer at the 114th Annual Meeting of the American Association for Cancer Research, 2023 (AACR-2023)
  • In May 2022, Astellas pharma presented pharmacodynamics data from a preclinical trial of Sepantronium bromide in renal cell carcinoma at the 117th annual meeting of the American Urological Association

Product Name

Total Studies

maveropepimut-S (MVP-S)


sepantronium bromide (PC-002)


gataparsen (LY2181308)




Target Indication Analysis of Survivin Inhibitor

Survivin inhibitors are targeted therapeutic agents designed to block the activity of the survivin protein, which is overexpressed in various cancer types, including breast, lung, colon, and ovarian cancers. By inhibiting survivin, these drugs aim to induce apoptosis (programmed cell death) in cancer cells, thereby hindering tumor growth and promoting cancer cell death. The goal of survivin inhibitors is to offer a promising and potentially more selective approach to cancer treatment, with the hope of improving patient outcomes and providing a new avenue for combating the devastating impact of cancer on individuals worldwide.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Frequently Asked Questions

Survivin inhibitors drugs are used in the management of various cancer types, including breast, lung, colon, and ovarian cancers.

The Survivin inhibitor market is poised for continued growth due to its potential as a novel and targeted approach to cancer treatment. Key drivers include promising clinical trial results demonstrating the efficacy of Survivin inhibitors in specific cancer types, leading to increased adoption by healthcare providers.

The major players in this space are Marker Therap, AbbVie, Astellas, Cothera Biosci, EMD Serono, Eli Lilly, Enzon, and Erimos are pharmaceutical companies operating in the healthcare industry.

The survivin inhibitor market faces significant challenges due to limited clinical success and potential adverse effects associated with targeting survivin, a protein involved in apoptosis regulation. Additionally, the development of effective and safe survivin inhibitors has been impeded by the complex biological functions of survivin, making it difficult to achieve selective inhibition without impacting normal cellular processes.

  • Marker Therap
  • AbbVie
  • Astellas
  • Cothera Biosci
  • EMD Serono
  • Eli Lilly
  • Enzon
  • Erimos Pharma
  • Fosun Pharma
  • IMV Inc
  • IO Biotech
  • Ionis
  • MANA Therap
  • Menarini
  • MimiVax
  • NexImmune
  • PDC line Pharma